Joseph E. Gilliam Sells 3,328 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam sold 3,328 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $15,310,024.65. This trade represents a 3.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Glaukos Stock Up 1.9 %

Shares of GKOS stock opened at $151.22 on Thursday. Glaukos Co. has a one year low of $74.75 and a one year high of $151.92. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The stock has a fifty day moving average price of $138.89 and a 200 day moving average price of $128.72. The stock has a market cap of $8.34 billion, a P/E ratio of -50.07 and a beta of 1.03.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. During the same period last year, the firm earned ($0.50) EPS. The firm’s revenue for the quarter was up 23.9% compared to the same quarter last year. Analysts predict that Glaukos Co. will post -1.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on GKOS. Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and raised their target price for the company from $132.00 to $162.00 in a research note on Wednesday, December 11th. Stifel Nicolaus raised their price target on Glaukos from $145.00 to $153.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Stephens upgraded Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. Piper Sandler set a $140.00 target price on Glaukos in a research note on Thursday, October 17th. Finally, JPMorgan Chase & Co. lifted their price target on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $145.92.

Institutional Investors Weigh In On Glaukos

A number of institutional investors have recently added to or reduced their stakes in the stock. HighTower Advisors LLC raised its holdings in shares of Glaukos by 3.3% in the 3rd quarter. HighTower Advisors LLC now owns 3,207 shares of the medical instruments supplier’s stock worth $416,000 after buying an additional 103 shares in the last quarter. Values First Advisors Inc. acquired a new position in Glaukos during the third quarter worth $25,000. New York State Teachers Retirement System lifted its holdings in shares of Glaukos by 0.4% during the third quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock valued at $6,272,000 after acquiring an additional 200 shares during the period. KBC Group NV boosted its stake in shares of Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 201 shares in the last quarter. Finally, Inspire Investing LLC grew its holdings in shares of Glaukos by 6.9% in the 3rd quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier’s stock worth $416,000 after purchasing an additional 206 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.